Real-time tracking of complex ubiquitination cascades using a fluorescent confocal on-bead assay
The ubiquitin-proteasome system (UPS) controls the stability, localization and/or activity of the proteome. However, the identification and characterization of complex individual ubiquitination cascades and their modulators remains a challenge. Here, we report a broadly applicable, multiplexed, miniaturized on-bead technique for real-time monitoring of various ubiquitination-related enzymatic activities. The assay, termed UPS-confocal fluorescence nanoscanning (UPS-CONA), employs a substrate of interest immobilized on a micro-bead and a fluorescently labeled ubiquitin which, upon enzymatic conjugation to the substrate, is quantitatively detected on the bead periphery by confocal imaging.
UPS-CONA is suitable for studying individual enzymatic activities, including various E1, E2, and HECT-type E3 enzymes, and for monitoring multi-step reactions within ubiquitination cascades in a single experimental compartment. We demonstrate the power of the UPS-CONA technique by simultaneously following ubiquitin transfer from Ube1 through Ube2L3 to E6AP. We applied this multi-step setup to investigate the selectivity of five ubiquitination inhibitors reportedly targeting different classes of ubiquitination enzymes. Using UPS-CONA, we have identified a new activity of a small molecule E2 inhibitor, BAY 11-7082, and of a HECT E3 inhibitor, heclin, towards the Ube1 enzyme.
As a sensitive, quantitative, flexible, and reagent-efficient method with a straightforward protocol, UPS-CONA constitutes a powerful tool for interrogation of ubiquitination-related enzymatic pathways and their chemical modulators, and is readily scalable for large experiments.
KeywordsUbiquitin Inhibitors Confocal fluorescence Bead-based assay Ubiquitination assay
Post-translational modification of protein substrates by the small modifier protein ubiquitin regulates the stability, localization, interactions, and activity of a substantial fraction of the proteome. Disruption of the ubiquitin-proteasome system (UPS) is associated with many diseases, including cancer, neurological disorders, and immune system dysfunction , and as a consequence is a high priority area for drug discovery. In the canonical ubiquitination cascade, the C-terminal carboxylate of ubiquitin is first activated in an ATP-dependent fashion by an E1 ubiquitin-activating enzyme, followed by thioester transfer to an E2 ubiquitin-conjugating enzyme, before subsequent transfer via an E3 ubiquitin ligase to a substrate lysine residue and attachment through an isopeptide linkage. Repetition of this cascade enables a ubiquitin chain to be assembled on the substrate through conjugation of further ubiquitin moieties to one of the seven lysine residues on ubiquitin itself. Different ubiquitin chain linkages can specify different fates for the substrate. For example, K48-linked chains target substrates to the 26S proteasome for rapid degradation, while K63-linked chains can control the assembly of various protein complexes. Protein monoubiquitination also occurs frequently and can direct protein interactions, for example in intracellular vesicular trafficking. Various ubiquitin modifications can be read by dedicated reader domains and can be reversed through the action of specific deubiquitinating enzymes. The human genome encodes two E1 enzymes, 38 E2 enzymes, over 600 E3 enzymes, over 100 deubiquitinating enzymes, as well as various associated scaffolding subunits. The combinatorial promiscuity of ubiquitin system enzymes, including redundant substrate targeting by different E3s, has made the deconvolution of UPS-mediated control far more difficult than originally envisioned, with implications for UPS drug discovery. In addition, only a limited number of small molecule inhibitors of the UPS are available as mechanistic probes and most of these inhibitors are only poorly characterized for specificity . The dearth of reliable methods to assess molecular mode of action of chemical inhibitors with the necessary level of quantification, time resolution and specificity has hindered UPS drug discovery [3, 4, 5].
The confocal scanning technology (CONA) was originally developed to enable screening of combinatorial chemical libraries directly on the solid bead-based support, which in effect serves as a nanoscale assay compartment [6, 7, 8, 9, 10, 11]. The confocal sectioning of a monolayer of ~ 100-μm-sized beads imaged on a fluorescence microscope equipped with a scanning stage enables the high-throughput, highly sensitive detection of binding events between a bead-linked small molecule and a fluorescently labeled target protein in solution [6, 8]. Bead-based screening methods are miniaturized, versatile, highly sensitive, quantitative and fast, and have proven successful in identification of numerous small molecule and peptidomimetic binders and inhibitors against difficult protein targets, such as HuR, Importin beta, and LFA-1 [9, 10, 11].
To address the need for a robust technique attuned to the multitude of complex UPS reactions, we developed a fluorescence-based on-bead confocal imaging method, termed UPS-confocal fluorescence nanoscanning (UPS-CONA), for quantitative characterization of dynamic ubiquitination reactions in real time. We demonstrate suitability of UPS-CONA for studying E1, E2, and HECT E3 activities, both individually and in an integrated enzyme reaction cascade. The modularity and miniaturization of UPS-CONA, in combination with high sensitivity, provides a powerful tool for deciphering multi-step reactions by tracking the kinetics of ubiquitin transfer in real time. In proof-of-concept experiments, we apply UPS-CONA to investigate the specific activity of selected ubiquitination inhibitors and uncover novel inhibitory activities.
A confocal on-bead ubiquitination assay—the concept
Monitoring activities of E1, E2, and HECT E3 enzymes
Multiplexing bead populations in a single well
Tracking a multi-step ubiquitination cascade
Target deconvolution of ubiquitination inhibitors
Despite the therapeutic potential of the UPS in cancer and other disease areas, the activity and selectivity of many reported molecules that modulate the UPS are not fully characterized. In particular, assessment of the specificity of a potential inhibitor towards more than one reaction in a cascade requires development of multiple assays. We reasoned that an ideal assay system for addressing target specificity in the UPS should allow enzymatic reactions of the entire cascade to be monitored in parallel. Quantitative and time-resolved monitoring of ubiquitin transfer through the E1-E2-E3 cascade to the final substrate would provide mechanistic insight into the potential effects of an inhibitor at each step.
This information would allow triage of hit compounds that lacked the necessary specificity for lead development. To investigate whether UPS-CONA can be used to assess selectivity of ubiquitination inhibitors, we used our multi-step ubiquitination assay to test a selection of known ubiquitination inhibitors: an E1 inhibitor PYR-41 , the E2 inhibitors BAY 11-7082  and CC0651 [20, 21], and the HECT E3 inhibitors clomipramine  and heclin  (Additional file 1: Figure S5).
BAY 11-7082 inhibits Ube1
Mechanistic insights into enzyme inhibition
As the UPS-CONA readout combines quantitative and time-resolved detection of ubiquitination, we reasoned that it should be possible to resolve selected aspects of inhibition mechanisms. We therefore analyzed the dose-response effects of the aforementioned inhibitors on ubiquitin loading on Ube1 on beads, followed by reduction with DTT (Fig. 6b). In this format, the signal remaining after DTT treatment would correspond to ubiquitin that interacted with Ube1 through a thioester-independent mechanism. Analysis of the inhibition curves revealed that BAY 11-7082 inhibited up to ~ 50% of ubiquitin loading onto Ube1 (Fig. 6a, b), which suggested that this compound may act on only one ubiquitin binding site of Ube1. Since ubiquitin cannot occupy the second thioester site on Ube1 without binding first to the adenylation site, we inferred that the thioester site was likely affected. The DTT-resistant signal was dose-dependent, reaching ~ 60% at highest compound concentration used (Fig. 6b, right). This result indicated that the proportion of the thioester-bound ubiquitin was reduced by BAY 11-7082, consistent with an effect on the thioester site on Ube1. This mechanism implied a similar mode of action of BAY 11-7082 as described previously for E2 enzymes, by forming a covalent adduct with the reactive cysteine residues . In contrast, the effect of heclin on Ube1 was less pronounced and similar to PYR-41 in the shape of the inhibition curve (Fig. 6a, b). However, the proportion of DTT-resistant signal remained unchanged upon increasing heclin concentrations (Fig. 6b, right), suggesting that heclin acts through a different mechanism than PYR-41 or BAY 11-7082 . As revealed by dose-response curves and DTT treatment, CC0651 and clomipramine did not affect Ube1 activity, which was confirmed in SDS-PAGE ubiquitination assays.
Discussion and conclusions
We developed and validated an on-bead confocal detection method called UPS-CONA which is suitable for studying individual enzymatic activities, including various E1, E2, and HECT-type E3 enzymes. We also show that the various ubiquitin-E1-E2-E3 reaction intermediates of a ubiquitination cascade can be followed in a single reaction vessel using an exemplary enzymatic cascade from Ube1 through Ube2L3 to E6AP in a time-resolved manner. A dynamic, confocal detection of fluorescent ubiquitin conjugates ensures a timely, sensitive readout, and a straightforward protocol can be easily automatized for large-scale experiments. Furthermore, our integrated assay is suitable for studying effects of small molecule inhibitors upstream or downstream of the presumptive target against which an inhibitor was originally identified.
The multi-step monitoring capability of the UPS-CONA assay allowed for identification of a new inhibitory activity of BAY 11-7082 towards Ube1. This information is important for the ubiquitin community, as this activity will need to be taken into account in assays using this compound so far known as a broad E2 enzyme, but not E1 enzyme inhibitor . To make decisions on further development of any hit compound from a binder screen or an enzymatic screen, the selectivity information is critically important. UPS-CONA resolves biochemical mode of action in one well of a 384-well plate with picomole amounts of reagents, and may be used for selectivity assays, either based on enzyme or ubiquitin mutations, or structure-activity relationships of hit series. Given the small amounts of enzymes with conventional tags needed for UPS-CONA, combined with the sensitivity and time-resolved capabilities demonstrated in this work, this method should facilitate the study of reaction mechanisms, mode of action of inhibitors, and high-throughput screening campaigns.
UPS-CONA may be parallelized further using different bead sizes to allow simultaneous monitoring of ubiquitination of different substrates in the same reaction or adapted to monitor deubiquitinating enzyme and ubiquitin-binding domain activities. Ubiquitin-like modifiers, for example SUMO or NEDD8, may also be monitored in similar assay formats or used for bead-based deconvolution of multiple modification types on a single substrate. Given the robustness of the on-bead fluorescent ring readout to interfering fluorescence from the reactions solutions [7, 8], a lysate-based assay may also be used to study reactions under more physiological conditions, without the need for prior purification of reaction components.
As a technique which requires protein immobilization, bead-based biosensors like UPS-CONA have limitations similar to other comparable methods, particularly plate-based biosensors such as enzyme-linked immunosorbent assay (ELISA) or surface plasmon resonance (SPR). Often equilibrium constants, and kinetic rate constants of binding and enzymatic reactions with one reaction partner immobilized to a bead matrix or plate surface, differ from the constants obtained from experiments performed in homogeneous solution . While the assay may not reflect the exact kinetic parameters measured in solution, it is of great value for a larger-scale comparative evaluation of activities and in particular of inhibitor selectivity, which we showcase in this work. Related to the immobilization method, contrary to other techniques, UPS-CONA offers a great choice of attachment type which can be used according to the available protein tagging type and reagents. In our study, we used Ni2+NTA-His6-tag affinity for protein attachment to beads; however, other types of immobilization methods can be used such as antibodies and biotin-streptavidin. Ideally, to avoid any leakage of proteins from the beads, covalent attachment would be preferable, such as amine crosslinking with N-hydroxysuccinimide esters. As any other fluorescence-based method, UPS-CONA may be affected by fluorescence interference, quenching or bleaching. Although we did not observe such effects under conditions used in this work, this aspect has to be taken into consideration when designing experiments to make sure that suitable controls are included for normalization. Another limitation of the technique may come from the instrumentation used. Confocal scanning under high magnification will provide great resolution, but may be relatively slow and therefore not suitable for monitoring fast reactions, as we demonstrated with ubiquitin charging onto Ube1. However, slower reactions and end point effects are easily measured and, with the advancements in microscopy techniques, the assay detection speed is likely to improve.
The suitability of off-the-shelf confocal imaging instrumentation and commercially available reagents should enable UPS-CONA technology to become a broadly applicable method. UPS-CONA should therefore be of value for exploring the interactions and activities within combinatorially complex UPS cascades, for identification and characterization of new small molecule probes, and for facilitating UPS drug discovery.
BAY 11-7082, clomipramine, and heclin were purchased from Sigma-Aldrich (cat. no B5556, C7291 and SML1396, respectively). PYR-41 was purchased from Calbiochem (cat. no 662105) and CC0651 was provided by the Tyers group. The masses and purity of compounds were confirmed by analytical HPLC and LC/MS.
The following proteins were purchased from BostonBiochem: wild type ubiquitin (cat. no U-100H); untagged human recombinant ubiquitin-activating enzyme (UBE1) (cat. no E-304); N-terminally His6-tagged human recombinant ubiquitin-activating enzyme (UBE1) (cat. no E-305); human recombinant E6AP (UBE3A) with a C-terminal His6-tag (cat. no E3–230).
Protein expression and purification
His6-tagged Ube2L3 was expressed from pET28a-LIC (provided by the Sicheri group) in BL21(DE3) E. coli. One-liter cultures were grown at 37 °C in LB and induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 20 °C overnight. Cells were harvested by centrifugation at 4000 rpm, 4 °C, lysed in lysis buffer (50 mM sodium phosphate buffer pH 8, 400 mM NaCl, 10 mM imidazole, 10 mM β-mercaptoethanol, protease inhibitor cocktail (Roche) with lysozyme (Sigma-Aldrich), and Benzonase Nuclease (Sigma-Aldrich, cat. no E8263)), and sonicated on ice for 1 min in 10-s pulses at 50% of maximum power (Sonic VibraCell). The lysate was cleared by centrifugation at 4000 rpm, 4 °C, and incubated in rotation with pre-equilibrated 2 to 4 mL of 50% slurry Ni2+ NTA beads (Qiagen) for 2 h at 4 °C prior to standard histidine-tag protein purification according to manufacturer’s instructions. Proteins were eluted in lysis buffer containing 300 mM imidazole. To obtain untagged Ube2L3, the His6-tag was removed with thrombin. Protein purity was analyzed by SDS-PAGE and by analytical HPLC. Protein concentration was measured by UV-Vis (NanoDrop, ThermoScientific) based on absorption at 280 nm and stray light correction at 330 nm.
Expression, purification, and labelling of Cys0-ubiquitin
Cys0-Ub (ubiquitin with an N-terminal cysteine insertion) was expressed as TEV-cleavable histidine6, glutathione-S-transferase (GST) fusion from pETM-30 plasmid (provided by the Sicheri lab) in BL21(DE3) E. coli. Harvested cells were lysed and purified on Ni2+NTA resin as above, then the tag was cleaved overnight with TEV protease in 10 mL elution buffer with 2 mM DTT. Contaminants, TEV, and cleaved tag were removed by perchloric acid precipitation (pH 4.5) and centrifugation at 4 °C, 14000 rpm. Cys0-Ub was then dialyzed into 50 mM NaOAc pH 4.5 and purified on a 5-mL MonoS column (Pharmacia Biotech) using ÄKTA Explorer FPLC purification system (Amersham Pharmacia Biotech). Elution volumes of 0.5 mL were analyzed by SDS-PAGE and pure fractions were pooled and dialyzed into 20 mM HEPES, 100 mM NaCl, and 0.5 mM TCEP pH 7.0. The concentration was measured by UV-Vis (NanoDrop, Thermo Scientific) and adjusted to 500 μM using Amicon-Ultra filter spin columns with 3 kDa cutoff (Merck Millipore).
For labelling, maleimide-Cy5 (GE Healthcare) was dissolved under argon in 100% dry DMSO to obtain 50 mM stock solution, aliquoted, and kept at − 20 °C. Labelling reactions were performed in 100-μL volumes. For 3 h at 25 °C, 300 μM of Cys0-Ub was incubated with 2.5 mM maleimide-Cy5 on a shaking platform, then purified by size exclusion chromatography over a PD10 column (GE Healthcare). Elution fractions were analyzed by HPLC, and the fractions labeled Cy5-Ub with < 1% free Cy5-maleimide were pooled together. The purity of the sample was assessed by SDS-PAGE and the Cy5-ubiquitin concentration was measured by UV-Vis (NanoDrop, Thermo Scientific) based on Cy5 absorption at 649 nm, prior to being aliquoted and stored at − 80 °C.
The proteins (E1, E2s, ubiquitin) were run on 12% Bolt Bis-Tris Plus SDS-PAGE gels (Thermo Fisher Scientific), transferred to a 0.2-μm nitrocellulose membrane (BioRad), and incubated with mouse anti-6His-tag antibody (1:500, Roche, cat. no 11 922 416 001), mouse anti-Ub antibody (1:1000, Enzo, cat. no ADI-SPA-203) or rabbit anti-Ube1 antibody (1:1000, Enzo, cat. no BML-PW8395), and infrared dye-coupled goat anti-mouse or anti-rabbit secondary antibody (1:20,000, LI-COR, cat. no 925-32210 and 925-32211). Blots were scanned using an infrared imager (Odyssey, LI-COR Biosciences) at 800 nm.
Gel-based Ube1 activity assay
In 10-μL volumes, 200 nM Ube1 was pre-incubated with compounds in indicated concentrations or DMSO as control for 15 min in 50 mM Tris pH 7.5, 5 mM MgCl2, before adding 5 μM WT Ub and 1 μM ATP. The reactions were incubated at 30 °C for 5 min and stopped by adding SDS loading buffer. The samples were resolved by SDS-PAGE and visualized by Coomassie staining (SimplyBlue™, Invitrogen), or by Western blotting with anti-Ube1 and anti-Ub antibodies.
Nickel nitrilotriacetic acid (Ni2+NTA) agarose micro-beads were purchased from Qiagen (cat. no. 30250). Before use, beads were filtered through various mesh sizes (40, 70, 80, 100, and 120 μm) using cell strainers (Corning cat. 352340, 352350, and 352360) or nylon-woven net filters (Millipore cat. no. NY8004700 and NY2H04700) to obtain beads in specific size ranges. Beads were then washed thoroughly with binding buffer (0.3 M NaCl, 20 mM HEPES pH 7.5, 0.01% Triton X-100) and brought back to 50% slurry. One microliter of 100–120 μm filtered beads per well of a 384-well plate was used to form a monolayer with around 50% coverage of the well bottom surface. The volumes and amounts were scaled up according to the required number of wells.
Immobilizing protein on beads
The estimated bead loading capacity as provided by the manufacturer is around 50 mg per 1 mL of the 50% slurry solution for a protein of around 30 kDa. One microliter of beads would have a protein loading amount equal to 50 μg of protein. Generally, we used a maximum of 0.5 μM in 20 μL of on-bead protein per well corresponding to 300 ng, which is over 160-fold below saturating amounts. The optimal amount of protein on bead for effective signal detection was determined by using a His6-tagged Emerald Green Fluorescent Protein (emGFP) standard. A linear correlation between the amount of on-bead emGFP and ring intensity held for values equal to and below 10 pmoles/well (Additional file 1: Figure S1). It was also verified that His6-tagged proteins were stably attached to the beads for several hours under typical experimental conditions, which is probably due to fast on and off rates corresponding to micromolar dissociation constants given by the tagging system (Additional file 1: Figure S7). The beads were incubated with the desired quantity of His6-tagged protein (typically 2.5 pmoles per well, or 125 nM) in ice-cold binding buffer on a shaker at 1000 rpm for at least 30 min at 8 °C. After incubation, the beads were extensively washed with binding buffer and the volume of bead solution was adjusted to 10 μL per well.
On-bead ubiquitination reaction
Beads with attached proteins were distributed in 10-μL volumes into microplate wells (black, flat glass bottom 384-well plate, MMI PS384B-G175) using a wide bore pipette tip (Rainin RC-250W). Ubiquitination mixes were prepared to obtain final concentrations in 20 μL as follows: 500 nM Cy5-labeled ubiquitin (Cy5-Ub), 50 nM Ube1, 0.5 μM Ube2L3, 5 mM ATP where appropriate, in 50 mM Tris pH 7.5, 5 mM MgCl2. Ubiquitin-activating reactions with on-bead Ube1 were performed with Cy5-Ub and ATP. Ubiquitin-charging reactions with on-bead Ube2L3 were performed with Cy5-Ub, Ube1, and ATP. Ubiquitin-charging/conjugation to on-bead E6AP were performed with Cy5-Ub, Ube1, Ube2L3, and ATP. The plate was incubated at 37 °C and the reactions were monitored over time. For determination of proportion of thioester-bound ubiquitin, 50 mM DTT was added at the end of the reaction and imaged again after 10 min incubation.
Multi-step ubiquitination reactions
For one well of a 384-well plate, 20 μL reactions were prepared containing 0.2 μL of 50% slurry small (70–80 μm diameter) Ni2+NTA agarose beads with 50 nM immobilized Ube1; mixed with 1 μL of large (100–120 μm) beads with immobilized 200 nM E6AP, and 500 nM Cy5-Ub in 50 mM Tris pH 7.5, 5 mM MgCl2. The beads were preincubated with compounds for 15 min in concentrations as indicated. Reactions were imaged on the Opera™ High Content Screening System (Perkin Elmer) before and after adding 5 mM ATP. At this point, 500 nM Ube2L3 similarly preincubated with compounds was added where appropriate and the reaction was imaged over time for at least 2 h. For inhibitor activity evaluation, the well averages were normalized against the DMSO control and the data was fitted using non-linear regression to a four-parameter logistic IC50 function using GraFit 7 .
Images were acquired on the Opera™ High Content Screening System (Perkin Elmer) at 30.0 μm above well bottom, at × 20 magnification with air lenses (20× Air LUCPLFLN, NA = 0.45). Brightfield and two fluorescent channels for detection of emGFP and Cy5 were used in the following settings: excitation wavelength 640 nm (Cy5) and 488 nm (emGFP); emission filters: 690/70 nm (Cy5) and 520/35 nm (emGFP). Typically, 77 images from the center of the well were taken to ensure near-full well coverage and to visualize > 100 beads per well, and a well sublayout with 20% image field overlap was applied to allow consequent image stitching. Image data were analyzed using ImageJ and a custom MatLab script.
Full well images are stitched together from multiple individual microscope images using the Grid/Collection Stitching Plugin for ImageJ . The stitched images from each channel, either brightfield or fluorescent, are analyzed for each well in a well plate. The detection in the brightfield channel allows detection of all the beads in a given well, including those with only weak or no fluorescence signal. An edge detection algorithm and Gaussian filtering is applied to the image, followed by a circular Hough transfer to identify circles in the image within a required diameter range (typically between 100 and 120 μm) representing the beads. A canonical list of bead positions and radii in each well is compiled by correlating the beads detected from all the imaging channels. Beads which are incomplete and overlapping or coincide with the image edges are removed from the list. A pre-determined number of profiles (typically 10) is taken across each bead. The peaks representing the “ring” and the mean of the 20–80th percentiles of the profile intensity between the peaks representing the background bead intensity are identified for each profile. A profile “intensity” is computed by subtracting the background from the peak intensity. The mean of these background-corrected ring intensity measurements for each bead is computed, giving the bead intensity. If more than one fluorophore is used in the experiment, the ratio of fluorescence emission intensities of two fluorophores detected on bead is used for an enhanced quantification as it allows for correction against a reference fluorophore, such as a second label on the assayed protein immobilized on beads. Ratiometric analysis is performed by calculating the ratio of the bead intensity of the same bead in multiple fluorescent channels. The mean bead ring intensity of each well in each channel is calculated as the average bead intensity of all the beads in the well. For each well, the mean bead ring intensity and standard deviation are calculated.
This work was supported by the Wellcome Trust PhD Programme grant no. 089397/Z/09/Z. M.A. also acknowledges financial support from the Scottish Universities Life Sciences Alliance (SULSA- http://www.sulsa.ac.uk), the Medical Research Council ((MRC- www.mrc.ac.uk, J54359) Strategic Grant, and from the European Community’s 7th Framework Program (FP7/2007–2013) under grant agreement no 278568 “PRIMES”. F.S. and M.T. acknowledge support from the Canadian Institutes for Health Research (MOP-126129). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
JK co-invented and developed the assay, designed, performed, and analyzed the experiments, and wrote the manuscript; NP contributed to confocal microscopy experiments, produced labeled ubiquitin, and participated in data analysis; DE created the software for data analysis and supported analysis of the results; SM cloned the fluorescent proteins into expression vectors; IP helped with data analysis; MT co-invented the assay; DC and FS provided plasmids and protein reagents and supported with ubiquitin purification and labelling; SS contributed to data analysis and to figure generation; MA developed the concept of expanding on-bead screening to enzymatic reactions exemplified in this work with UPS-CONA, co-invented the assay, and wrote the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
The University Court of the University of Edinburgh filed an international patent application no. PCT/GB2015/052565 which covers parts of the method.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 1.Petroski MD. The ubiquitin system, disease, and drug discovery. BMC Biochem. 2008;9 Suppl 1:S7. doi: https://doi.org/10.1186/1471-2091-9-S1-S7.
- 6.Hintersteiner M, Buehler C, Uhl V, Schmied M, Müller J, Kottig K, et al. Confocal nanoscanning, bead picking (CONA): PickoScreen microscopes for automated and quantitative screening of one-bead one-compound libraries. J Comb Chem. 2009;11:886–94. https://doi.org/10.1021/cc900059q.CrossRefPubMedGoogle Scholar
- 7.Hintersteiner M, Kimmerlin T, Kalthoff F, Stoeckli M, Garavel G, Seifert J-M, et al. Single bead labeling method for combining confocal fluorescence on-bead screening and solution validation of tagged one-bead one-compound libraries. Chem Biol. 2009;16:724–35. https://doi.org/10.1016/j.chembiol.2009.06.011.CrossRefPubMedGoogle Scholar
- 10.Hintersteiner M, Ambrus G, Bednenko J, Schmied M, Knox AJS, Meisner N-C, et al. Identification of a small molecule inhibitor of importin β mediated nuclear import by confocal on-bead screening of tagged one-bead one-compound libraries. ACS Chem Biol. 2010;5:967–79. https://doi.org/10.1021/cb100094k.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Beaudenon S, Huibregtse JM. HPV E6, E6AP and cervical cancer. BMC Biochem. 2008;9 Suppl 1 Suppl 1:S4. doi: https://doi.org/10.1186/1471-2091-9-S1-S4.
- 19.Strickson S, Campbell DG, Emmerich CH, Knebel A, Plater L, Ritorto MS, et al. The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochem J. 2013;451:427–37. https://doi.org/10.1042/BJ20121651.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Rossi M, Rotblat B, Ansell K, Amelio I, Caraglia M, Misso G, et al. High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy. Cell Death Dis. 2014;5:e1203. https://doi.org/10.1038/cddis.2014.113.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, et al. Novel inhibitors of cytokine-induced I B phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997;272:21096–103. https://doi.org/10.1074/jbc.272.34.21096.CrossRefPubMedGoogle Scholar
- 25.Leatherbarrow RJ. GraFit Version 7. Horley, U.K: Erithacus Software Ltd.; 2009.Google Scholar
- 27.Koszela J, Pham NT, Evans D, Mann S, Perez-Pi I, Shave S, Ceccarelli DFJ, Sicheri F, Tyers M, Auer M. Real-time tracking of complex ubiquitination cascades using a fluorescent confocal on-bead assay, [dataset]. School of Biological Sciences: University of Edinburgh; 2018. https://doi.org/10.7488/ds/2384 Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.